Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
NCT05829460 on ClinicalTrials.gov · last registry update 2026-01-12
Withdrawn before anyone was enrolled. Due to report 30 April 2030. Primary outcome, as filed: Number of patients with endometrial hyperplasia free biopsy with uterine preservation. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- WITHDRAWN
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Washington University School of Medicine
- Sponsor type
- Other
- Enrollment
- 0
- Started
- 2025-03-12
- Primary completion
- 2030-04-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Number of patients with endometrial hyperplasia free biopsy with uterine preservation
Conditions studied
Endometrial Hyperplasia
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.